MRNA
Price
$30.49
Change
+$0.21 (+0.69%)
Updated
Jul 3 closing price
Capitalization
11.79B
25 days until earnings call
OKYO
Price
$2.78
Change
-$0.13 (-4.47%)
Updated
Jul 3 closing price
Capitalization
104.04M
30 days until earnings call
Interact to see
Advertisement

MRNA vs OKYO

Header iconMRNA vs OKYO Comparison
Open Charts MRNA vs OKYOBanner chart's image
Moderna
Price$30.49
Change+$0.21 (+0.69%)
Volume$6.97M
Capitalization11.79B
OKYO Pharma
Price$2.78
Change-$0.13 (-4.47%)
Volume$81.43K
Capitalization104.04M
MRNA vs OKYO Comparison Chart in %
Loading...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OKYO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MRNA vs. OKYO commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRNA is a Hold and OKYO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (MRNA: $30.49 vs. OKYO: $2.78)
Brand notoriety: MRNA: Notable vs. OKYO: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MRNA: 60% vs. OKYO: 43%
Market capitalization -- MRNA: $11.79B vs. OKYO: $104.04M
MRNA [@Biotechnology] is valued at $11.79B. OKYO’s [@Biotechnology] market capitalization is $104.04M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MRNA’s FA Score shows that 1 FA rating(s) are green whileOKYO’s FA Score has 0 green FA rating(s).

  • MRNA’s FA Score: 1 green, 4 red.
  • OKYO’s FA Score: 0 green, 5 red.
According to our system of comparison, MRNA is a better buy in the long-term than OKYO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MRNA’s TA Score shows that 5 TA indicator(s) are bullish while OKYO’s TA Score has 4 bullish TA indicator(s).

  • MRNA’s TA Score: 5 bullish, 4 bearish.
  • OKYO’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, MRNA is a better buy in the short-term than OKYO.

Price Growth

MRNA (@Biotechnology) experienced а +10.71% price change this week, while OKYO (@Biotechnology) price change was +14.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

MRNA is expected to report earnings on Jul 31, 2025.

OKYO is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRNA($11.8B) has a higher market cap than OKYO($104M). OKYO YTD gains are higher at: 141.760 vs. MRNA (-26.671).
MRNAOKYOMRNA / OKYO
Capitalization11.8B104M11,346%
EBITDA-3.2BN/A-
Gain YTD-26.671141.760-19%
P/E RatioN/AN/A-
Revenue3.14BN/A-
Total Cash5.98BN/A-
Total Debt745MN/A-
FUNDAMENTALS RATINGS
MRNA: Fundamental Ratings
MRNA
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
62
P/E GROWTH RATING
1..100
2
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
MRNAOKYO
RSI
ODDS (%)
Bearish Trend 4 days ago
72%
Bearish Trend 4 days ago
71%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
87%
Momentum
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
80%
MACD
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
56%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
56%
Advances
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 5 days ago
87%
Declines
ODDS (%)
Bearish Trend 19 days ago
85%
Bearish Trend 20 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 4 days ago
89%
Aroon
ODDS (%)
N/A
Bullish Trend 4 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OKYO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CVRT32.350.27
+0.83%
Calamos Convertible Equity Alt ETF
BIBL42.010.27
+0.65%
Inspire 100 ETF
XBJA30.270.06
+0.20%
Innovator US Eq Acclrtd 9 Bffr ETF Jan
PBNV28.02N/A
N/A
PGIM S&P 500 Buffer 20 ETF - Nov
SPBO29.05-0.06
-0.21%
SPDR® Portfolio Corporate Bond ETF

MRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRNA has been loosely correlated with BNTX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNA jumps, then BNTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRNA
1D Price
Change %
MRNA100%
+0.69%
BNTX - MRNA
50%
Loosely correlated
+1.61%
ARCT - MRNA
50%
Loosely correlated
+1.17%
CRSP - MRNA
48%
Loosely correlated
+0.97%
NVAX - MRNA
45%
Loosely correlated
+0.59%
RGNX - MRNA
45%
Loosely correlated
+1.39%
More

OKYO and

Correlation & Price change

A.I.dvisor tells us that OKYO and ACUT have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OKYO and ACUT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OKYO
1D Price
Change %
OKYO100%
-4.47%
ACUT - OKYO
28%
Poorly correlated
N/A
XRTX - OKYO
27%
Poorly correlated
+0.87%
DYN - OKYO
27%
Poorly correlated
-2.01%
MRNA - OKYO
27%
Poorly correlated
+0.69%
NXTC - OKYO
26%
Poorly correlated
+1.75%
More